



Date: January 20, 2026

To,

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Sub.: Application for in-principle approval under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the proposed scheme of Amalgamation of Prvi Fine Sciences Private Limited ("PFSPL" or Transferor Company 1) and Prvi Biotechnologies Private Limited ("PBPL" or Transferor Company 2) with Prvi Speciality Chemicals Limited ("PSCL" or Transferee Company").

Ref: NSE requirement letter ref. no. NSE/LIST/52681 dated January 13, 2026

Dear Sir/Madam,


With reference to the captioned subject, please find below point wise responses to the clarification sought:

Sr. No	Clarification Sought	Response
1.	It has been observed that the response submitted by the Company for query no. 9 of Requirement letter dated January 01, 2026, is inconsistent with the query asked. Kindly note point no.2 of Undertaking with respect to Explanatory statement is in draft format, you are requested to revise and submit the same.	The revised undertaking is enclosed herewith as Annexure I .
2.	Kindly confirm if the Audited financials shared by the Company for PFSPL for last 3 years is on consolidated or standalone basis. If the same is on standalone basis, you are requested to provide it on consolidated basis.	The Audited financials shared by the Company for PFSPL for last 3 years are on standalone basis. PFSPL does not hold any investment (subsidiary/ associate) hence requirement for consolidation of financials is not applicable.
3.	Kindly confirm whether there are any Suit filed cases reported by credit bureau, any show cause notice(s)/ order(s) issued by any regulatory authority/ any disciplinary action/ litigation/ any pending loans/ defaults in respect of payment of interest and/or principal to lenders involving Vinaykumar Doppalapudi Rao, Moneymart Securities Pvt	We hereby confirm that except as disclosed in Annexure II , there are no suit filed cases reported by credit bureau, any show cause notice(s)/ order(s) issued by any regulatory authority/ any disciplinary action/ litigation/ any pending loans/ defaults in respect of payment of interest and/or principal to lenders involving Vinaykumar Doppalapudi Rao, Moneymart Securities Private Limited, MM Infra &



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Prvi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privicom | CIN: L15140MH1985PLC286828



Sr. No	Clarification Sought	Response
	Ltd, Mm Infra & Leasing Private Limited, SBI Multi Asset Allocation Fund, Naresh Madhu Tejwani, Sanjeev Gajanan Patil which are pending as on date.	Leasing Private Limited, Naresh Madhu Tejwani and Sanjeev Gajanan Patil. Further, we confirm that SBI Multi Asset Allocation Fund is a public shareholder and the same confirmation for SBI Multi Asset Allocation Fund is not applicable.

We request you to kindly take our above submissions on record.

For, Privi Speciality Chemicals Limited

Ashwini Saumil Shah
Company Secretary & Compliance Officer
Membership No.: A58378



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privil House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.prixi.com | CIN: L15140MH1985PLC286828



Annexure - I

Date: January 20, 2026

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001 Scrip Code: 530117	To, National Stock Exchange of India Limited Exchange Plaza, Plot No.C-1, G Block Bandra Kurla Complex, Bandra (East) Mumbai - 400051 Symbol: PRIVISCL
---	---

Subject: Undertaking pursuant to Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations").

Dear Sirs,

We, Privi Speciality Chemicals Limited, the Transferee Company in the scheme of Amalgamation of Privi Fine Sciences Private Limited ("Transferor Company 1"), Privi Biotechnologies Private Limited ("Transferor Company 2") and Privi Speciality Chemicals Limited ("Transferee Company") and their respective shareholders (hereinafter referred to as "Scheme of Amalgamation") hereby undertake that in connection with the above application, we hereby confirm that:

1. In the explanatory statement to be forwarded by the company to the shareholders u/s 230 of the Companies Act 2013, we shall disclose the pre and post scheme (expected) capital structure and shareholding pattern, the "fairness opinion" obtained from an Independent merchant banker, information about unlisted companies involved in the scheme as per the format provided for abridged prospectus of the SEBI ICDR Regulations, the Complaint report and the observation letter issued by the stock exchange.
2. There is no reclassification of promoters pursuant to scheme. Hence, the compliance with the Companies Act, 2013, SEBI (ICDR) Regulations, 2018, SEBI (LODR) Regulations, 2015 and any other applicable laws for reclassification of promoters is not applicable.

For Privi Speciality Chemicals Limited

Ashwini Saumil Shah
Company Secretary
ICSI Mem. No.: A58378



Date: January 20, 2026

Place: Navi Mumbai



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | **Email:** enquiry@privi.co.in | **Web:** www.privicom | **CIN:** L15140MH1985PLC286828



Annexure - II

Details of suit filed cases reported by credit bureau, any show cause notice(s)/ order(s) issued by any regulatory authority/ any disciplinary action/ litigation/ any pending loans/ defaults in respect of payment of interest and/or principal to lenders.

Name	Assessment Year	Amount of Demand in Rs. Lakhs	Brief About the matter
Moneymart Securities Private Limited	2022-23	1,643.07	Demand on account of assessment order passed u/s. 143(3) of Income Tax Act, 1961, which has been stayed by Income Tax Authorities as the appeal with CIT-Appeal Pune has been preferred.
MM Infra & Leasing Private Limited	2020-21	65.14	Demand on account of assessment order passed u/s. 144 of Income Tax Act, 1961, the demand is not correct, which has been stayed by Income Tax Authorities as the appeal with CIT- Appeal Pune has been preferred.
	2022-23	60.05	Demand on account of assessment order passed u/s. 143(3) of Income Tax Act, 1961, the demand is not correct, which has been stayed by Income Tax Authorities as the appeal with CIT-Appeal Pune has been preferred.

For Privi Speciality Chemicals Limited


Ashwini Saumil Shah
Company Secretary
ICSI Mem. No.: A58378



Date: January 20, 2026

Place: Navi Mumbai



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.prixi.com | CIN: L15140MH1985PLC286828